Ibogaine’s legal status varies significantly by country, and the regulatory landscape is shifting. This guide summarizes the legal posture in jurisdictions where ibogaine treatment is currently administered, with source citations for each claim. Status was last reviewed on the publication date above; the law changes — verify current status with a qualified attorney in the relevant jurisdiction before making decisions.
United States: Schedule I
Ibogaine is Schedule I under the federal Controlled Substances Act (21 CFR 1308.11), the most restrictive classification — meaning federal law treats ibogaine as having no accepted medical use and a high potential for abuse.
In practical terms:
- No legal commercial administration. Ibogaine cannot be prescribed, possessed for therapeutic use, or sold for treatment in the US.
- Clinical research requires an FDA Investigational New Drug (IND) application. A small number of FDA-authorized research protocols exist, but they are limited in scope and not available to most patients.
- Recent legislative developments: Texas approved $50 million for state-funded ibogaine clinical trials in 2025. The federal NDAA Section 723 (FY2024) authorizes Department of Defense funding for ibogaine clinical trials in active-duty service members with PTSD or TBI. Neither of these changes the immediate legal status for civilian commercial treatment.
The asymmetry is striking: federal investment in research is increasing while clinical access for civilians still requires international travel. We cover the policy landscape in detail in Ibogaine for veterans: federal recognition and the access gap.
Source: 21 CFR 1308.11 (Schedule I controlled substances list); DEA enforcement; FDA IND framework.
Mexico: legal under medical / wellness regulation
Mexico is the most common destination for international ibogaine treatment, hosting clinics in Cancún, Tijuana, Rosarito, Cabo San Lucas, Cozumel, Playa del Carmen, Tepoztlán, and San Miguel de Allende.
Ibogaine is not specifically scheduled under Mexican federal drug law (Ley General de Salud, Article 245 controlled substances list). Treatment facilities operate under wellness and medical regulation rather than under a specific ibogaine licensing regime.
Practical implications:
- Clinics typically operate as licensed medical facilities or as wellness retreats with medical staff on site.
- The regulatory framework is permissive but not specifically tailored to psychedelic-assisted therapy.
- Cross-border legal questions (US patients receiving treatment in Mexico) are governed by Mexican law on Mexican soil.
Source: Mexican Federal Law of Health (Ley General de Salud); status pending editorial verification of specific statutory references.
Costa Rica: legal under medical / wellness regulation
Costa Rica has a similar regulatory framework to Mexico — ibogaine is not specifically scheduled under Costa Rican drug law (Law No. 8204, Ley sobre Estupefacientes), and treatment is offered under medical and wellness regulation.
A note of caution: several international clinics market “Costa Rica” treatment programs while operating from facilities in Mexico or elsewhere. Confirm the physical location of treatment during your evaluation. Some clinics have legitimate Costa Rica facilities; others use Costa Rica as a destination keyword.
Source: Costa Rica Law No. 8204; status pending editorial verification.
Portugal: therapeutic use under medical supervision
Portugal decriminalized personal use of all drugs in 2001 under Decree-Law 130-A/2001, a landmark public-health-framework reform. While this law applies primarily to personal possession, it created an environment in which therapeutic use of substances like ibogaine is possible under medical supervision in licensed clinics.
A small number of clinics operate in Portugal, primarily in the Alentejo region. They function under medical authority within Portugal’s health regulatory framework.
Source: Decree-Law 130-A/2001 (drug decriminalization framework); status pending editorial verification.
Bahamas: legal under medical regulation
Ibogaine is not specifically scheduled under Bahamian drug law (Dangerous Drugs Act). Treatment is administered under medical regulation, and ibogaine clinics have operated in the Bahamas for over a decade. Caribbean facilities tend to position as luxury treatment destinations with longer programs.
Source: Bahamas Dangerous Drugs Act; ibogaine not listed in scheduled substances. Pending editorial verification of specific statutory references.
Netherlands: gray area
Ibogaine is not specifically scheduled under the Dutch Opium Act (Opiumwet) — neither in List I (hard drugs) nor in List II (soft drugs). Several clinics have operated in the Netherlands historically, though the regulatory posture is more ambiguous than in Mexico, Portugal, or Bahamas.
The Dutch situation is best described as a regulatory gray zone:
- Treatment facilities are neither explicitly authorized nor explicitly prohibited
- Enforcement has historically been minimal
- The legal posture could change without notice
- Patients and providers should consult a Dutch attorney before relying on this status
This is meaningfully different from Mexico, Costa Rica, or Portugal — where clinics operate within a defined medical or wellness regulatory framework. In the Netherlands, clinics operate in the absence of clear regulation.
Source: Dutch Opium Act (Opiumwet); ibogaine not listed in Lists I or II as of last review. Status pending editorial verification.
Brazil: hospital prescription only (limited)
São Paulo legalized prescription-based ibogaine use in hospital settings in 2016, making Brazil one of the few jurisdictions with explicit therapeutic authorization. However, the framework is restricted to hospital prescription and supervision; consumer-marketable retreats and standalone clinics in Brazil are uncommon. Patient access is mediated by physicians, not by direct booking with a clinic.
Source: São Paulo state regulatory authorization; pending editorial verification of specific statutory references.
Other jurisdictions
- Canada: Not specifically scheduled federally; some provincial frameworks differ. Consult Canadian counsel.
- United Kingdom: Class A controlled substance (similar to Schedule I).
- Australia: Schedule 9 (most restrictive).
- Most EU countries: Vary by member state. Many treat ibogaine as a non-scheduled compound that can be administered under medical supervision; enforcement varies.
- Colombia, Peru: Legal gray area; some facilities operate without explicit authorization.
How legal status is changing
The federal-investment-versus-clinical-access asymmetry described above — research and policy advancing domestically in the US while clinical care remains international — is the central legal-policy story for ibogaine right now.
Recent developments worth tracking:
- Texas SB 2308 (signed 2025). $50M state appropriation for ibogaine clinical trials, with 25% of any resulting state revenue earmarked for veterans programs. UTHealth Houston and UTMB Galveston were selected in March 2026 to lead a statewide research consortium.
- NDAA Section 723 (FY2024). $10M in DoD research grants for psychedelic-assisted therapies, including ibogaine, for active-duty service members with PTSD and TBI. Champion: Rep. Morgan Luttrell (R-TX).
- Stanford 2024 study (Nature Medicine). First large peer-reviewed study of ibogaine in veterans with TBI; magnesium-ibogaine protocol; significant improvements in PTSD, depression, and disability metrics.
- State-level psychedelic services programs. Oregon Measure 109 (2020) and Colorado Proposition 122 (2022) created psilocybin-services frameworks; ibogaine-specific frameworks have not yet followed but the regulatory pattern is the same.
These shifts do not currently provide US civilian patients with legal commercial access to ibogaine. They do, however, indicate a substantial increase in research funding and political legitimacy — which has historically been the precursor to formal regulatory change.
This is not legal advice
We summarize publicly available sources; we are not licensed attorneys. The legal status of ibogaine treatment in any specific jurisdiction can change without notice, and individual patient circumstances (citizenship, prior convictions, medical history) introduce additional considerations we cannot evaluate generally.
If you are making a decision that depends on specific legal status — particularly if you are crossing borders to receive treatment, or if you have legal exposure that could be affected by the trip — consult a qualified attorney in the relevant jurisdiction before relying on summaries like this one.
Next steps
- How to choose an ibogaine clinic: a safety checklist
- Ibogaine treatment cost: what to expect
- Browse providers by country and city
This information is for educational purposes only and is not medical or legal advice.